Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 50.70
-0.90 (-1.74%)
Sep 9, 2025, 1:30 PM CST
Tanvex BioPharma Market Cap
Tanvex BioPharma has a market cap or net worth of 12.09 billion as of September 9, 2025. Its market cap has increased by 43.42% in one year.
Market Cap
12.09B
Enterprise Value
13.06B
Revenue
110.99M
Ranking
n/a
PE Ratio
n/a
Stock Price
50.70
Market Cap Chart
Since August 13, 2015, Tanvex BioPharma's market cap has decreased from 16.77B to 12.09B, a decrease of -27.90%. That is a compound annual growth rate of -3.19%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 9, 2025 | 12.09B | 13.03% |
| Dec 31, 2024 | 10.70B | 22.75% |
| Dec 29, 2023 | 8.71B | -29.59% |
| Dec 30, 2022 | 12.38B | -39.56% |
| Dec 30, 2021 | 20.48B | 106.96% |
| Dec 31, 2020 | 9.89B | -9.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Caliway Biopharmaceuticals | 395.51B |
| PharmaEssentia | 177.30B |
| Bora Pharmaceuticals Co., LTD. | 91.34B |
| Lotus Pharmaceutical | 50.62B |
| Lumosa Therapeutics | 44.05B |
| Oneness Biotech | 37.16B |
| Polaris Group | 29.89B |
| Pell Bio-Med Technology | 28.68B |